AP2A2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population with targeted disruption of the AP2A2 gene in the A-549 human lung carcinoma cell line. This product provides a heterogeneous pool of cells enabling loss-of-function studies for clathrin-mediated endocytosis research. The polyclonal format avoids clonal selection, mirroring population-level responses to gene disruption.
The A-549 cell line originates from a 58-year-old Caucasian male with lung carcinoma and displays epithelial morphology, establishing it as a widely employed in vitro model for lung adenocarcinoma. These cells are especially relevant for investigations into cancer cell biology, including mechanisms of migration, invasion, and drug resistance, and they provide a context for examining endocytic processes inherent to lung epithelial pathology.
AP2A2 encodes the alpha-adaptin subunit of the AP-2 complex, a heterotetramer critical for clathrin-mediated endocytosis. This complex functions at the plasma membrane by connecting clathrin to transmembrane cargo, thereby initiating vesicle formation. AP2A2 directly interacts with clathrin heavy chain, the beta, mu, and sigma AP2 subunits, and endocytic accessory proteins including epsin and AP180. Upstream regulation involves membrane lipid PIP2 and AAK1 kinase-mediated phosphorylation, while cargo binding stabilizes the complex. Targeted cargoes include transferrin receptor and EGFR, whose internalization delivers them to early endosomes. Consequently, AP2A2 disruption leads to defective clathrin-coated vesicle formation and aberrant receptor trafficking, perturbing downstream signaling pathways.
In the A-549 background, AP2A2 knockout disrupts clathrin-dependent endocytosis, providing a unique tool to probe endocytosis-mediated modulation of oncogenic signaling. Impaired internalization of EGFR and other growth factor receptors can alter proliferation, migration, and sensitivity to therapeutics. This model is particularly suited for studying how receptor trafficking defects influence lung adenocarcinoma progression, bridging fundamental cell biology with translational research on diseases like Alzheimer’s and cancer.
This polyclonal knockout product supports a broad range of assays: transferrin uptake for monitoring endocytosis, immunofluorescence to visualize clathrin and cargo co-localization, and Western blotting for quantifying receptor expression. Endocytosis inhibition studies, migration/invasion assays, and drug sensitivity analyses can dissect functional impacts on cancer cell behavior. Researchers studying vesicle-mediated transport, receptor internalization, and signaling dynamics will find these cells useful. For technical assistance and product details, please contact Ascent Research.
